The company was founded in 1997 by Dr Graham March, a pharmacist with substantial experience of the formulation of medicines gained whilst working at major pharmaceutical companies and within the UK’s National Health Service.
The team of formulation experts at Veriton Pharma has since developed more than 60 “specials” for a targeted range of therapeutic areas. The company has grown rapidly, supplying products to more than 25 countries.
In May 2020 Veriton Pharma were acquired by SERB Pharmaceuticals, a leading European specialty pharmaceutical group focused on prescription medicines that address rare and life-threatening diseases. SERB’s focus on critical care and answering unmet needs is closely aligned with Veriton’s history and approach, and as part of an integrated group they can take their growth to the next level.
Unlicensed 'Special' Products
Our heritage of developing tailor-made medications enables Veriton Pharma to provide a range of unlicensed therapy options for those patients whose clinical needs are not met by licensed medications.
News
- SERB Announces the Acquisition of Veriton Pharma
- SAPHNA Annual Conference 2019: HEALTH FOR ALL CHILDREN
SAPHNA Annual Conference 2019: 18th June in Manchester We are delighted to be attending the upcoming SAPHNA Annual Conference; HEALTH FOR ALL CHILDREN – School and Public Health Nurses Turning the Tide…. Read More
- Young Epilepsy online guide for school
Veriton Pharma is pleased to announce the online publication of the charity Young Epilepsy’s online guide for schools. This comprehensive resource aimed at improving the management and support of children with epilepsy… Read More
- Young Epilepsy and Veriton Pharma Ltd announce key partnership agreement in support of the charity’s ‘Rules 4 Schools’ campaign
Young Epilepsy and Veriton Pharma Ltd (Veriton) have announced a key agreement, where the organisations will work in partnership to deliver the ‘Rules 4 Schools” element of the charity’s newly… Read More